The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase IB study to evaluate the safety of selinexor in combination with multiple standard chemotherapy agents in patients with advanced malignancies.
 
Aung Naing
Research Funding - Amplimmune; ARMO BioSciences; Atterocor; Baxter (I); EMD Serono; Healios; Incyte; Karyopharm Therapeutics; MedImmune; NCI; Novartis; Regeneron
Travel, Accommodations, Expenses - ARMO BioSciences
 
Siqing Fu
No Relationships to Disclose
 
Apostolia Maria Tsimberidou
Research Funding - Baxter (Inst); Bayer (Inst); EMD Serono (Inst); Foundation Medicine (Inst); ONYX (Inst)
 
Shubham Pant
Consulting or Advisory Role - Celgene; Halozyme
 
Sarina Anne Piha-Paul
No Relationships to Disclose
 
Filip Janku
Consulting or Advisory Role - Deciphera; Foundation Medicine; Guardant Health; Novartis; Sequenom; Trovagene
Research Funding - Agios; Astellas Pharma; Biocartis; BioMed Valley Discoveries; Deciphera; Foundation Medicine; Fujifilm; Novartis; Piqur; Plexxikon; Roche; Symphony Evolution; Trovagene
Other Relationship - Bio-Rad
 
David S. Hong
Stock and Other Ownership Interests - MolecularMatch; Oncorena
Honoraria - Adaptimmune; Baxter; Bayer; Merrimack
Consulting or Advisory Role - Baxter; Bayer
Research Funding - Amgen; AstraZeneca; Daiichi Sankyo; Eisai; Genentech; Lilly; Merck; Mirati Therapeutics; miRNA Therapeutics; Novartis; Pfizer
Travel, Accommodations, Expenses - Loxo; miRNA Therapeutics
Other Relationship - Oncorena
 
Rivka R. Colen
No Relationships to Disclose
 
Brett W. Carter
No Relationships to Disclose
 
Elizabeth Evans
Travel, Accommodations, Expenses - Karyopharm Therapeutics
 
Hussein Abdul-Hassan Tawbi
Consulting or Advisory Role - Novartis
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst); Novartis (Inst)
 
Daniel D. Karp
No Relationships to Disclose
 
Vivek Subbiah
Research Funding - Novartis, GSK, Nanocarrier, NorthWest Biotherapeutics, Roche/Genentech, BergPharma, Bayer, Incyte, FujiFilm, Pharmamar, D3, Pfizer Amgen, Abbvie, Multivir, Bluprint Medicines.
Travel, Accommodations, Expenses - Novartis, Pharmamar, Fujifilm
 
Rony Dev
No Relationships to Disclose
 
Kenneth R. Hess
Travel, Accommodations, Expenses - Angiochem
 
Naoto T. Ueno
No Relationships to Disclose
 
George R. Simon
No Relationships to Disclose
 
Michael J. Overman
Consulting or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb; Merrimack; Roche/Genentech; sirtex Medical
Research Funding - Amgen; Bristol-Myers Squibb; Celgene; MedImmune; Merck; Roche
 
Robert L. Coleman
Honoraria - NCCN
Consulting or Advisory Role - Clovis Oncology; DOD-CDRMP; Esperance Pharmaceuticals; Genentech/Roche; NCCN
Research Funding - Amgen; Array BioPharma; AstraZeneca/MedImmune; Clovis Oncology; Esperance Pharmaceuticals; Johnson & Johnson; Merck; OncoMed
Travel, Accommodations, Expenses - Amgen; Array BioPharma; AstraZeneca/MedImmune; Bayer; Clovis Oncology; Gradalis; Merck; Millennium; New Mexico Cancer Center; Research to Practice; Roche/Genentech; University of California, Irvine; University of Cincinnati Cancer Center; University of Miami
 
Funda Meric-Bernstam
Honoraria - Genentech; Roche
Consulting or Advisory Role - Celgene; Clearlight Diagnostics; Genentech; Inflection Biosciences; Novartis; Pieris Pharmaceuticals; Roche
Research Funding - Aileron Therapeutics; AstraZeneca; Bayer; Calithera Biosciences; Curis; CytomX Therapeutics; Debiopharm Group; Effective Pharmaceuticals; Genentech; Jounce Therapeutics; Novartis; PUMA Biotechnology; Taiho Pharmaceutical; Verastem; Zymeworks